GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

Shares of GSK PLC GSK inched down 0.34% to £16.04 Wednesday ... Supported by world-class markets data from Dow Jones and ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine ...

Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity ...

Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.